About Retatrutide360

Retatrutide360 is an independent guide to retatrutide, the GIP, GLP-1 and glucagon triple agonist in development by Eli Lilly and Company. We are not affiliated with Lilly, with any clinic, or with any company that makes or sells the drug.

What we cover

Dosing, results, side effects, clinical trials, comparisons with other weight-loss medicines, and the practical questions people ask when they start looking into retatrutide. We plan more than a hundred guides and publish them in batches, each one written against the published trial data.

How we work

Every clinical number on this site links to the study, regulator page or company announcement it came from. When the evidence is thin we say so, and when new results land we update the pages they affect and change the date at the top. Our editorial policy explains the process in full.

How the site is funded

Some pages may include affiliate links. If you buy through one, we may earn a commission at no extra cost to you. That never changes what the evidence says, and our affiliate disclosure explains how it works.

Talk to us

Spotted an error or a newer study? Email hello@retatrutide360.com and we will check it.